Tefibazumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | Clumping factor A |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Formula | C6548H10122N1730O2034S44 |
| Molar mass | 147.590 kDa g·mol−1 |
Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]
It was developed by Inhibitex.[3]
See also
References
- ^ Clinical trial number NCT00198289 at ClinicalTrials.gov
- ^ PMID 18221183
- ^ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |